FDA-approved
Hormones & metabolism
Exenatide
Evidence
FDA approved
Class
GLP-1 receptor agonist
KEY TAKEAWAY
Exenatide is a synthetic version of exendin-4, a peptide found in the saliva of the Gila monster. It is sold as Byetta and Bydureon. The FDA approved exenatide (Byetta) in 2005 as the first GLP-1 receptor agonist, and a once-weekly form (Bydureon) in 2012.
Written by the Veylo editorial team · Updated
November 2026
What it is
GLP-1 receptor agonist
Approved for
Type 2 diabetes
Key fact
The FDA approved exenatide (Byetta) in 2005 as the first GLP-1 receptor agonist, and a once-weekly form (Bydureon) in 2012.
Route
Twice-daily or weekly subcutaneous injection
Evidence strength
FDA approved
Exenatide is a synthetic version of exendin-4, a peptide found in the saliva of the Gila monster. It is sold as Byetta and Bydureon.
It activates GLP-1 receptors, which raises insulin release when blood sugar is high, slows stomach emptying and lowers appetite.
The FDA approved exenatide (Byetta) in 2005 as the first GLP-1 receptor agonist, and a once-weekly form (Bydureon) in 2012.
Type 2 diabetes.
Nausea is the most common effect. Pancreatitis is a rare serious risk, and the weekly form carries a boxed warning about thyroid C-cell tumors.
U.S. FDA prescribing information for Exenatide. DailyMed, National Library of Medicine.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.